TEM-89 beta-lactamase produced by a Proteus mirabilis clinical isolate: New complex mutant (CMT 3) with mutations in both TEM-59 (IRT-17) and TEM-3

Citation
C. Neuwirth et al., TEM-89 beta-lactamase produced by a Proteus mirabilis clinical isolate: New complex mutant (CMT 3) with mutations in both TEM-59 (IRT-17) and TEM-3, ANTIM AG CH, 45(12), 2001, pp. 3591-3594
Citations number
25
Categorie Soggetti
Microbiology
Journal title
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
ISSN journal
00664804 → ACNP
Volume
45
Issue
12
Year of publication
2001
Pages
3591 - 3594
Database
ISI
SICI code
0066-4804(200112)45:12<3591:TBPBAP>2.0.ZU;2-S
Abstract
TEM-89 (CMT-3) is the first complex mutant beta -lactamase produced by a cl inical strain of Proteus mirabilis (strain Pm 631). This new enzyme, which has a pI of 6.28, is derived from TEM-3 and has a single amino acid substit ution also encountered in TEM-59 (inhibitor-resistant TEM beta -lactamase I RT-17): Ser-130 to Gly. TEM-89 hydrolyzed penicillins to the same extent th at TEM-3 did but lost almost all hydrolytic activity for cephalosporins and , like TEM-59, was highly resistant to inhibitors.